Labcorp (NYSE:LH) EVP Kathryn Kyle Sells 762 Shares

Labcorp Holdings Inc. (NYSE:LH) EVP Kathryn Kyle sold 762 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the transaction, the executive vice president owned 3,813 shares in the company, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Trading Up 3.4%

Shares of Labcorp stock opened at $270.99 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. Labcorp Holdings Inc. has a 52 week low of $241.81 and a 52 week high of $293.72. The stock has a 50 day moving average price of $262.74 and a two-hundred day moving average price of $265.74. The stock has a market capitalization of $22.22 billion, a PE ratio of 24.00, a price-to-earnings-growth ratio of 1.83 and a beta of 0.90.

Labcorp (NYSE:LH) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities analysts anticipate that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Institutional Investors Weigh In On Labcorp

A number of institutional investors have recently added to or reduced their stakes in LH. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Labcorp in the 4th quarter worth approximately $26,000. Hilton Head Capital Partners LLC bought a new stake in Labcorp during the fourth quarter worth $27,000. JPL Wealth Management LLC purchased a new position in Labcorp in the third quarter worth $28,000. Eagle Bay Advisors LLC bought a new position in Labcorp in the 4th quarter valued at $29,000. Finally, DV Equities LLC bought a new position in Labcorp in the 4th quarter valued at $29,000. 95.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on LH. Robert W. Baird set a $334.00 price target on shares of Labcorp in a research report on Friday, May 1st. JPMorgan Chase & Co. increased their price objective on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Piper Sandler raised their target price on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Finally, Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus price target of $308.00.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.